Hypera S.A. (BVMF:HYPE3)

Brazil flag Brazil · Delayed Price · Currency is BRL
22.37
-0.30 (-1.32%)
Oct 6, 2025, 11:46 AM GMT-3
-1.32%
Market Cap14.35B
Revenue (ttm)6.66B
Net Income (ttm)742.68M
Shares Out632.94M
EPS (ttm)1.16
PE Ratio19.38
Forward PE7.91
Dividend1.17 (5.16%)
Ex-Dividend DateSep 29, 2025
Volume262,400
Average Volume2,183,800
Open22.82
Previous Close22.67
Day's Range22.33 - 22.82
52-Week Range16.62 - 28.87
Beta0.30
RSI39.77
Earnings DateOct 28, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]

Sector Healthcare
Founded 1999
Employees 10,481
Stock Exchange Brazil Stock Exchange
Ticker Symbol HYPE3
Full Company Profile

Financial Performance

In 2024, Hypera's revenue was 7.44 billion, a decrease of -5.97% compared to the previous year's 7.91 billion. Earnings were 1.34 billion, a decrease of -18.63%.

Financial Statements

News

There is no news available yet.